Home › NDC Lookup › Ingredients › Penicillin V Potassium › 16714-0235-02
⚪image loading
(from DailyMed)

Penicillin V Potassium 500 mg Tablet, Film Coated, 1,000-count — NDC 16714-235-02 (Billing 16714-0235-02)

by NorthStar Rx LLC · 1000 TABLET, FILM COATED in 1 BOTTLE

This is a package of 1,000 tablets of Penicillin V Potassium 500 mg Tablet, Film Coated from NorthStar Rx LLC, marketed since Apr 2008 and currently FDA-listed; retail pharmacies pay about $0.0985 per tablet (NADAC).

NDC 16714-0235-02
🏷️ FDA NDC (as labeled) 16714-235-02 billing pads the product segment with a zero
This package
Contains1,000-count Cost per ea$0.0985 NADAC Per package$98.50 / 1000 tablets Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.3776/unit · Part D plans $0.1279/unit — full pricing hub ↓
Product page 16714-0235-01 Also comes in: 100 tablets 16714-235-01
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 16714-235-02 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
16714 labeler · 235 product · 02 package
Package marketed since
Apr 29, 2008
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
1,000 EA per package
Barcode (UPC)
0316714234014, 0316714235011
Medicaid fills, this package
1,124 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 16714-235-02
Product NDC 16714-235
11-digit billing NDC 16714023502
NCPDP billing unit EA — each (per item)
RxCUI 834061, 834102
UNII 146T0TU1JB
UPC 0316714234014, 0316714235011
Application # ANDA065435
SPL Set ID ec25ce45-c0b2-45fa-9211-77f283aad4bd
Established class (EPC) Penicillin-class Antibacterial
Chemical class Penicillins
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2008-04-29
Route ORAL
Dosage form TABLET, FILM COATED
Substance PENICILLIN V POTASSIUM
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 01100040100315
GPI class Penicillin V Potassium
GCN Seq No 008880
GCN 39055
HICL code 003942
Ingredient (HICL) Penicillin V Potassium
HIC1 code W
Therapeutic class — broad (HIC1) Anti-Infecting Agents
HIC2 code W1
Therapeutic class — intermediate (HIC2) Antibiotics
HIC3 code W1A
Therapeutic class — specific (HIC3) Penicillin Antibiotics
AHFS code 08:12.16.04
AHFS class Natural Penicillin Antibiotics
FDB label name PENICILLIN VK 500 MG TABLET
FDB brand name Penicillin V Potassium
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 008880
  • GCN: 39055
  • GPI-14 (Medi-Span): 01100040100315
  • HICL (First Databank): 003942
  • AHFS class code: 08:12.16.04
  • RxCUI (RxNorm): 834061
Why two NDCs? The FDA registers this code as 16714-235-02 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 16714-0235-02. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Penicillin-class Antibacterial class.

Pharmacologic class Penicillin-class Antibacterial
Drug family (ATC) Beta-lactamase sensitive penicillins
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name PENICILLIN VK 500 MG TABLET Ingredient Penicillin V Potassium
📗 Our plain-language guide HelloPharmacist
  • It's used for mild to moderately severe bacterial infections — things like strep throat, scarlet fever, certain respiratory infections from pneumococcal bacteria, mild skin infecti...
  • What kinds of infections does Penicillin V Potassium actually treat?
  • You can take it either way — it won't upset most people's stomachs badly. That said, your body actually absorbs slightly more of the medication if you take it on an empty stomach....
  • Should I take it with food or on an empty stomach?
📖 Read our full Penicillin V Potassium guide →
7
Nutrient depletion considerations

Penicillin V Potassium may be associated with lower levels of 7 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Penicillin V Potassium nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.099 $98.50 / 1000 tablets
Medicaid paysCMS SDUD · 12 mo $0.3776 $377.60 / 1000 tablets
Medicare drug plans payPart D · Q2 2026 $0.1279 $127.90 / 1000 tablets
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.120 $0.091
▼ Down 2% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
16714-0235-01 16714-235-01 Main listing 100 TABLET, FILM COATED in 1 BOTTLE $0.0985 / ea $9.85 2008-04-29 — Active
16714-0235-02 You're viewing this 1000 TABLET, FILM COATED in 1 BOTTLE $0.0985 / ea $98.47 2008-04-29 — Active

You're viewing the largest of 2 pack sizes for this product.

This pack effectively ties for the lowest per-ea cost of the 2 priced pack sizes ($0.0985 NADAC).

This pack accounts for about 5.8% of this product's recent Medicaid fills; most go to the 100 tablets pack. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 1,000-count package — 1000 tablet, film coated in 1 bottle.
How does this package differ from NDC 16714-0235-01?
Both are Penicillin V Potassium 500 mg Tablet, Film Coated — the drug itself is identical. This page's package is the 1,000-count one, while NDC 16714-0235-01 is the 100 tablets package.
What NDC number is used to bill for this package of Penicillin V Potassium 500 mg Tablet, Film Coated?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Penicillin V Potassium 500 mg 00093-1174-01 Teva 100 tablets $0.098 AB Availability likely —
Penicillin V Potassium 500 mg 00143-9836-01 Hikma 100 tablets $0.098 AB Availability likely —
Penicillin V Potassium 500 mgthis 16714-0235-02 NorthStar 1000 tablets $0.098 AB Availability likely —
Penicillin V Potassium 500 mg 57237-0041-01 Rising 100 tablets $0.098 AB Availability likely —
Penicillin V Potassium 500 mg 65862-0176-01 Aurobindo 100 tablets $0.098 — Availability likely —
Penicillin V Potassium 500 mg 42708-0098-14 QPharma 14 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 43063-0557-04 PD-Rx 4 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 43063-0576-28 PD-Rx 28 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 43063-0614-40 PD-Rx 40 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 43063-0680-40 PD-Rx 40 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 43063-0780-06 PD-Rx 6 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 43063-0995-40 PD-Rx 40 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 50090-4651-00 A-S 40 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 50090-4652-01 A-S 12 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 50090-5543-00 A-S 6 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 50090-6675-00 A-S 40 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 63187-0756-20 Proficient 20 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 63187-0926-20 Proficient 20 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 63629-7623-01 Bryant 20 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 63629-7928-01 Bryant 40 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 63629-9110-01 Bryant 30 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 67296-2261-02 Redpharm 20 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 68071-3299-04 NuCare 4 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 68071-3640-03 NuCare 30 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 68071-4838-03 NuCare 30 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 68071-5081-06 NuCare 6 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 68788-8242-02 Preferred 28 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 70518-2758-00 REMEDYREPACK 30 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 70518-3441-00 REMEDYREPACK 1 tablet — AB Discontinued —
Penicillin V Potassium 500 mg 70518-4657-00 REMEDYREPACK 30 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 72789-0222-01 PD-Rx 100 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 62135-0099-01 Chartwell 100 tablets — AB FDA listed —
Penicillin V Potassium 500 mg 70518-2877-00 REMEDYREPACK 20 tablets — AB Discontinued —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2008
On the market since
Apr 2008
📍
2026
Currently FDA-listed
18 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Penicillin V Potassium inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

Loading inactive ingredients from the official FDA label in the background. No external source is being called by this page request.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerNorthStar Rx LLC
Application holderAUROBINDO PHARMA LTD
FDA applicationANDA065435 (ANDA)
Labeler code16714
First marketedApr 2008
Product typeHuman Prescription Drug
Portfolio414 products on file

More NDCs from NorthStar Rx LLC labeler code 16714

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 📚 References 📄 Package Label / Principal Display Panel
🎯 Indications and Usage ~2 min read ▾

INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium and other antibacterial drugs, penicillin V potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriologic studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage.

Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal Infections (without bacteremia) Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas.

NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal Infections Mild to moderately severe infections of the respiratory tract.

Staphylococcal infections – penicillin G-sensitive Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent’s gingivitis and pharyngitis) Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin.

NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract 1 .

Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen.

NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association 1 .

⏱️ Dosage and Administration ~1 min read ▾

DOSAGE AND ADMINISTRATION The dosage of Penicillin V should be determined according to the sensitivity of the causative microorganisms and the severity of infection, and adjusted to the clinical response of the patient. The usual dosage recommendations for adults and children 12 years and over are as follows: Streptococcal Infections Mild to moderately severe - of the upper respiratory tract and including scarlet fever and erysipelas: 125 to 250 mg (200,000 to 400,000 units) every 6 to 8 hours for 10 days. Pneumococcal Infections Mild to moderately severe - of the respiratory tract, including otitis media: 250 to 500 mg (400,000 to 800,000 units) every 6 hours until the patient has been afebrile for at least 2 days.

Staphylococcal Infections Mild infections of skin and soft tissue (culture and sensitive tests should be performed): 250 to 500 mg (400,000 to 800,000 units) every 6 to 8 hours. Fusospirochetosis (Vincent’s infection) of the oropharynx. Mild to moderately severe infections: 250 to 500 mg (400,000 to 800,000 units) every 6 to 8 hours.

For the prevention of recurrence following rheumatic fever and/or chorea: 125 mg to 250 mg (200,000 to 400,000 units) twice daily on a continuing basis. For prophylaxis against bacterial endocarditis 1 in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when undergoing dental procedures or surgical procedures of the upper respiratory tract: 2 gram of penicillin V (1 gram for children under 60 lbs.) 1 hour before the procedure, and then, 1 gram (500 mg for children under 60 lbs.) 6 hours later.

⛔ Contraindications 11 words ▾

CONTRAINDICATIONS A previous hypersensitivity reaction to any penicillin is a contraindication.

⚠️ Warnings ~1 min read ▾

WARNINGS SERIOUS AND OCCASIONALLY FATAL HYPERSENSITIVITY (anaphylactic) REACTIONS HAVE BEEN REPORTED IN PATIENTS ON PENICILLIN THERAPY. THESE REACTIONS ARE MORE LIKELY TO OCCUR IN INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY AND/OR A HISTORY OF SENSITIVITY TO MULTIPLE ALLERGENS. THERE HAVE BEEN REPORTS OF INDIVIDUALS WITH A HISTORY OF PENICILLIN HYPERSENSITIVITY WHO HAVE EXPERIENCED SEVERE REACTIONS WHEN TREATED WITH CEPHALOSPORINS.

BEFORE INITIATING THERAPY WITH PENICILLIN V POTASSIUM TABLETS, CAREFUL INQUIRY SHOULD BE MADE CONCERNING PREVIOUS HYPERSENSITIVITY REACTIONS TO PENICILLINS, CEPHALOSPORINS, OR OTHER ALLERGENS. IF AN ALLERGIC REACTION OCCURS, PENICILLIN V POTASSIUM TABLETS SHOULD BE DISCONTINUED AND APPROPRIATE THERAPY INSTITUTED. SERIOUS ANAPHYLACTIC REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE.

OXYGEN, INTRAVENOUS STEROIDS, AND AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISTERED AS INDICATED. Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including penicillin V potassium tablets, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile .

C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing strains of C. difficile cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use.

Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile , and surgical evaluation should be instituted as clinically indicated.

🤒 Adverse Reactions 106 words ▾

ADVERSE REACTIONS Although the incidence of reactions to oral penicillins has been reported with much less frequency than following parenteral therapy, it should be remembered that all degrees of hypersensitivity, including fatal anaphylaxis, have been reported with oral penicillin. The most common reactions to oral penicillin are nausea, vomiting, epigastric distress, diarrhea, and black hairy tongue. The hypersensitivity reactions reported are skin eruptions (maculopapular to exfoliative dermatitis), urticaria and other serum-sickness like reactions, laryngeal edema, and anaphylaxis.

Fever and eosinophilia may frequently be the only reaction observed. Hemolytic anemia, leukopenia, thrombocytopenia, neuropathy, and nephropathy are infrequent reactions and usually associated with high doses of parenteral penicillin.

🧬 Clinical Pharmacology ~1 min read ▾

CLINICAL PHARMACOLOGY Penicillin V exerts a bactericidal action against penicillin-sensitive microorganisms during the stage of active multiplication. It acts through the inhibition of biosynthesis of cell-wall mucopeptide. It is not active against the penicillinase-producing bacteria, which include many strains of staphylococci.

The drug exerts high in vitro activity against staphylococci (except penicillinase-producing strains), streptococci (groups A, C, G, H, L and M), and pneumococci. Other organisms sensitive in vitro to penicillin V are Corynebacterium diphtheriae , Bacillus anthracis, Clostridia, Actinomyces bovis , Streptobacillus moniliformis , Listeria monocytogenes, Leptospira, and Neisseria gonorrhoeae . Treponema pallidum is extremely sensitive.

The potassium salt of penicillin V has the distinct advantage over penicillin G in resistance to inactivation by gastric acid. It may be given with meals; however, blood levels are slightly higher when the drug is given on an empty stomach. Average blood levels are two to five times higher than the levels following the same dose of oral penicillin G and also show much less individual variation.

Once absorbed, penicillin V is about 80% bound to serum protein. Tissue levels are highest in the kidneys, with lesser amounts in the liver, skin, and intestines. Small amounts are found in all other body tissues and the cerebrospinal fluid.

The drug is excreted as rapidly as it is absorbed in individuals with normal kidney function; however, recovery of the drug from the urine indicates that only about 25% of the dose given is absorbed. In neonates, young infants, and individuals with impaired kidney function, excretion is considerably delayed. Microbiology Susceptibility Testing For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.

📦 How Supplied / Storage and Handling 136 words ▾

HOW SUPPLIED Penicillin V Potassium Tablets USP, 250 mg (400,000 units) are white to off-white, round shaped, biconvex, film-coated tablets debossed with ‘E’ and ‘84’ on one side and break line on the other side. Bottles of 100 NDC 16714-234-01 Bottles of 1,000 NDC 16714-234-02 Penicillin V Potassium Tablets USP, 500 mg (800,000 units) are white to off-white, capsule shaped, film-coated tablets, debossed with ‘E’ and a break line on one side and ‘8’ and ‘5’ separated with a break line on the other side. Bottles of 100 NDC 16714-235-01 Bottles of 1,000 NDC 16714-235-02 Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].

Dispense in a tight container, as defined in the USP. Keep tightly closed. Keep out of reach of children.

📋 Description 90 words ▾

DESCRIPTION Penicillin V is the phenoxymethyl analog of penicillin G. Penicillin V potassium is the potassium salt of penicillin V. Penicillin V potassium tablets, for oral administration, contain 250 mg (400,000 units) or 500 mg (800,000 units).

The 250 mg tablet is equivalent to 250 mg (400,000 units) penicillin V and the 500 mg tablet is equivalent to 500 mg (800,000 units) penicillin V. In addition, each tablet contains the following inactive ingredients: povidone, microcrystalline cellulose, talc, colloidal silicon dioxide, magnesium stearate, hypromellose, polyethylene glycol, and titanium dioxide. Chemical Structure

💬 Information for Patients 179 words ▾

Information for Patients Patients should be counseled that antibacterial drugs including penicillin V potassium should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When penicillin V potassium is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed.

Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by penicillin V potassium or other antibacterial drugs in the future. Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic.

If this occurs, patients should contact their physician as soon as possible.

⚠️ Precautions ~1 min read ▾

PRECAUTIONS Penicillin should be used with caution in individuals with histories of significant allergies and/or asthma. General Prescribing penicillin V potassium in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria. The oral route of administration should not be relied upon in patients with severe illness, or with nausea, vomiting, gastric dilatation, cardiospasm, or intestinal hypermotility.

Occasionally patients will not absorb therapeutic amounts of orally administered penicillin. In streptococcal infections, therapy must be sufficient to eliminate the organism (10-day minimum); otherwise the sequelae of streptococcal disease may occur. Cultures should be taken following completion of treatment to determine whether streptococci have been eradicated.

Prolonged use of antibiotics may promote the overgrowth of nonsusceptible organisms, including fungi. Should superinfection occur, appropriate measures should be taken. Information for Patients Patients should be counseled that antibacterial drugs including penicillin V potassium should only be used to treat bacterial infections.

They do not treat viral infections (e.g., the common cold). When penicillin V potassium is prescribed to treat a bacterial infection, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may: (1) decrease the effectiveness of the immediate treatment, and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by penicillin V potassium or other antibacterial drugs in the future.

Diarrhea is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and bloody stools (with or without stomach cramps and fever) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible.

📚 References 34 words ▾

REFERENCES 1. American Heart Association.1984. Prevention of bacterial endocarditis. Circulation 70(6):1123A – 1127A. Manufactured for: Northstar Rx LLC Memphis, TN 38141. Manufactured by: Aurobindo Pharma Limited Hyderabad–500 090, India. M.L. No.: 57/RR/AP/2003/F/R Revised: 09/2018

📄 Package Label / Principal Display Panel 76 words ▾

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 250 mg (100 Tablet Bottle) R x only NDC 16714-234-01 Penicillin V Potassium Tablets, USP 250 mg (400,000 Units) 100 Tablets NORTHSTAR TM PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 250 mg (100 Tablet Bottle)

PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg (100 Tablet Bottle) R x only NDC 16714-235-01 Penicillin V Potassium Tablets, USP 500 mg (800,000 Units) 100 Tablets NORTHSTAR TM PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 500 mg (100 Tablet Bottle)

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
1.1K
Units reimbursed last 4 qtrs
34K
Gross reimbursed last 4 qtrs
$12.8K
Avg / prescription
$11.42
Avg / unit
$0.3776
Latest quarter Q1 2026
195Rx
Medicaid pays / ea
$0.3776
gross reimbursed
vs
NADAC / ea
$0.0985
acquisition cost
=
Spread
+$0.2791
+283% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
32% FFS 68% MCO
Fee-for-service · 363 Rx Managed care · 761 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: 2,855 units · 48.3 per 100k residents WI Michigan: 2,530 units · 25.2 per 100k residents MI New York: 4,477 units · 22.9 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 538 units · 12.7 per 100k residents OR Nevada: no data reported NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: no data reported IA Illinois: 385 units · 3.1 per 100k residents IL Indiana: no data reported IN Ohio: 3,072 units · 26.1 per 100k residents OH Pennsylvania: 2,074 units · 16.0 per 100k residents PA New Jersey: no data reported NJ Massachusetts: no data reported MA California: no data reported CA Utah: no data reported UT Colorado: no data reported CO Nebraska: no data reported NE Missouri: 1,046 units · 16.9 per 100k residents MO Kentucky: 3,339 units · 73.8 per 100k residents KY West Virginia: no data reported WV Virginia: no data reported VA Maryland: 1,876 units · 30.4 per 100k residents MD Connecticut: no data reported CT Rhode Island: no data reported RI Arizona: no data reported AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: 1,132 units · 36.9 per 100k residents AR Tennessee: no data reported TN North Carolina: 2,551 units · 23.5 per 100k residents NC South Carolina: no data reported SC Delaware: no data reported DE Oklahoma: 1,216 units · 30.0 per 100k residents OK Louisiana: 2,820 units · 61.7 per 100k residents LA Mississippi: 3,714 units · 126 per 100k residents MS Alabama: no data reported AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: no data reported TX Florida: 364 units · 1.6 per 100k residents FL
Units reimbursed · per 100k residents
1.6126
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Mississippi 126 /100k
2 Kentucky 73.8 /100k
3 Louisiana 61.7 /100k
4 Wisconsin 48.3 /100k
5 Arkansas 36.9 /100k
6 Maryland 30.4 /100k
7 Oklahoma 30.0 /100k
8 Ohio 26.1 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
100 tablets16714-0235-01 18,324 Rx · $194,431
1000 tablets this page16714-0235-02 1,124 Rx · $12,833
Drug total (last 4 qtrs): 19,448 Rx · 536,092 units · $207,264 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Penicillin V Potassium — the program that covers self-administered drugs. 5 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Penicillin V Potassium. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$642.3K
Claims incl. refills
97K
Beneficiaries
84.2K
Spend / beneficiary
$7.63
Spend / claim
$6.62
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 16714-0234-01 · NorthStar 16714-0245-30 · Northstar →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.